Tested stronger combo for high-risk myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of multiple myeloma.
- Your myeloma must be “high risk” based on specific lab/genetic features, risk score (RISS-3), certain antibody types (IgD/IgE), or measurable tumor outside the bone marrow.
- Your disease must be measurable by blood or scan results (for example, blood protein level or light chains above set thresholds).
- You should have fairly strong body function tests: good blood counts, liver enzymes and bilirubin within allowed limits, and kidney function (eGFR) at least 40 (with an exception for myeloma-related kidney problems).
- You must be able to safely take study medicines: no significant uncontrolled heart/lung problems, and your nerve symptoms should not already be severe.
- You must agree to the study in writing and accept that you may get side effects or different effectiveness than expected.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations (DRd and VRd-lite) for older adults (65+) who are newly diagnosed with multiple myeloma. The goal is to see which combination works better and is easier to tolerate.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This trial tests a combination of three drugs (isatuximab, bortezomib, lenalidomide, and a steroid) for people with newly diagnosed multiple myeloma who are older or frail and cannot have a stem cell transplant. It focuses on those with a certain type of myeloma cell in their blood, to see if the treatment works well and is safe.
This trial tests a four-drug combination (daratumumab, cabozantinib, pomalidomide, and dexamethasone) for patients with multiple myeloma that is either not responding to initial treatment or has come back for the first time, especially if it is considered high-risk. The goal is to see if this new combination works better than standard options.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.